Latest Conference Articles

Martin Dahl, PhD, of AnaptysBio discusses the findings and limitations of a study analyzing use of ANB032 in patients with atopic dermatitis (AD).

The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.

When the same product comes to market with additional indications, irrational pricing decisions result in ever-increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.

Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.

The real-time monitoring of patients through medically integrated dispensing (MID) programs can reduce costs of care and remove barriers, said Christie Smith, PharmD, MBA, vice president, pharmacy and payer strategy, Cencora.

Just as it is important for retail analysts to understand the choices their customers make and why they may choose not to purchase a specific item, so is it important for the specialty pharmacy industry to understand the actions of prescribers and how the often inefficient prior authorization process affects patient outcomes.

Payer coverage of biosimilars is always shifting as new ones come to market, explained Tasmina Hydery, PharmD, MBA, BCGP, associate director in digital solutions, Cencora.

Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.

Asembia AXS24, which has record registration this year, will take place in Las Vegas, Nevada, April 28-May 2, at the Wynn & Encore Las Vegas.

Coverage from the Community Oncology Alliance Community Oncology Conference, held April 4-5, 2024, in Orlando, Florida.

At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.

The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.

Session speakers at the Academy of Managed Care Pharmacy (AMCP) 2024 annual conference share their favorite parts of the event and the key takeaways they will leave the conference with.

Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP, highlights the biggest threats concerning a cyberattack on oncology practices.

A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.

The findings suggest there are ongoing disparities between Black and White patients with hepatocellular carcinoma (HCC) in terms of both outcomes and health care resource utilization.

Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.

Leslie Fish, PharmD, senior vice president of pharmacy at IDP Analytics, LLC, reflects on the future of biosimilars and the impact they will have on managed care pharmacy settings to improve patient access to medications.

The Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting included multiple poster presentations featuring studies on atopic dermatitis, 2 of which focused on the impact of ruxolitinib cream monotherapy and educating managed care professionals.

Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy, discussed how providers can comfortably switch patients to biosimilars while minimizing anxieties, as well as the impacts prior authorization requirements can have on patient access.

Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), discusses upcoming policy initiatives and the current oncology landscape amid a health care cyberattack.

Martina Porter, MD, FAAD, vice chair of research, Department of Dermatology, Beth Israel Deaconess Medical Center, discusses efficacy and safety findings from a phase 2 study.

At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.

Yuqian Liu, PharmD, Magellan Rx Management, explores the current space of cell and gene therapies based on real-world data and potential emerging therapies in the future, while expanding upon long-term efficacy concerns.

Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.

Jenny Craven, PharmD, BCPS, of the University of California Davis Health reviews the finances associated with Emerging Therapy Committee and examines the benefits of the adoption process of new therapies.

Kimberly Westrich, MA, of the National Pharmaceutical Council, addresses the benefits of incorporating patient-centricity throughout the health care system to foster more accurate and better quality of care.

Sarah Bajorek, PharmD, MBA, BCACP, University of California, Davis Health, discusses notable gene therapies emerging into the market and strategies to proactively engage with a wide range of stakeholders during the integration of a new gene therapy.